Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | WDR5 | P61964 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839543 | 0.86 | GAA (0.67) | ALDH1A1LMNAGAAPOLBKMT2A | |
| SCHEMBL23043630 | 0.84 | GAA (0.69) | ALDH1A1LMNAGAAPOLBKMT2A | |
| SCHEMBL29979387 | 0.84 | GAA (0.69) | ALDH1A1LMNAGAAPOLBKMT2A | |
| SCHEMBL398803 | 0.83 | ALDH1A1 (0.61) | SIRT6ALDH1A1LMNAGAAPOLB | |
| SCHEMBL3313887 | 0.83 | GAA (0.72) | SIRT6ALDH1A1LMNAGAAPOLB | |
| SCHEMBL15961236 | 0.83 | SIRT6 (0.59) | SIRT6ALDH1A1LMNAGAAPOLB | |
| SCHEMBL2461666 | 0.83 | ALDH1A1 (0.66) | SIRT6ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL30410222 | 0.83 | ALDH1A1 (0.61) | SIRT6ALDH1A1LMNAGAAPOLB | |
| SCHEMBL30464734 | 0.83 | ALDH1A1 (0.66) | SIRT6ALDH1A1LMNAGAAKMT2A | |
| SCHEMBL9404875 | 0.82 | POLB (0.51) | ALDH1A1LMNAGAAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612149-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094962-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| CN-109734674-B | Aniline WDR5 protein-protein interaction inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-26 | — | — | CN | disclosed |
| CN-110746424-A | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| CN-109734674-A | Phenyl amines WDR5 protein-protein interaction inhibitor and its preparation method and purposes | 中国药科大学 | 2019-05-10 | — | — | CN | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2334301-B1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO SA (CH) | 2018-02-14 | — | — | EP | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| CN-105163738-A | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RES INC | 2015-12-16 | — | — | CN | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8815872-B2 | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| CN-102143750-B | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH | 2014-04-02 | — | — | CN | disclosed |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| CN-102143750-A | Macrocyclics pyrimidines as aurora kinase inhibitors | MERCK PATENT GMBH | 2011-08-03 | — | — | CN | disclosed |
| EP-2334301-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | Merck Serono SA (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010028116-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | SIRT6 1320/4885ALDH1A1 4078/4885LMNA 4652/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | SIRT6 1320/4885ALDH1A1 4078/4885LMNA 4652/4885 |
| US-20110294801-A1 | MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS | AURKC, AURKA, AURKB | SIRT6 2185/4885ALDH1A1 4424/4885LMNA 2969/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | SIRT6 1320/4885ALDH1A1 4078/4885LMNA 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.